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ABSTRACT
Purpose: Short bowel syndrome (SBS) is the main
cause of intestinal failure. Intravenous supplementation
(parenteral support [PS]) helps patients regain health
but can affect patients' health-related quality of life
(HRQoL). The value of health states associated with
the number of days on PS per week is unknown in the
United Kingdom. The objectives of the present study
were to develop health state vignettes for SBS and PS,
and to estimate health state utilities by using the time
trade-off (TTO) technique.
Methods: Vignettes were developed and reviewed
through various processes. Eight states described the
impact of 0 days (weaned off PS) through to 7 days
on PS; each state comprised the conditions, symptoms,
treatments, and impacts related to EuroQol-5
dimensions. A sample of the UK general public viewed
each state in interviews; they provided ratings using a
visual analog scale and utility scores using the TTO.
Participants completed background questionnaires.
Findings: One hundred participants rated and
valued each health state. Visual analog scale and utility
scores showed a steady decline for the health states
associated with increasing numbers of days on PS.
With “full health” equivalent to a utility score of 1, the
most burdensome state was “7 days on PS” (mean [SD]
utility score, 0.36 [0.35]), whereas weaned off (“0 days
on PS”) showed the least burden (0.82 [0.22]).
Implications: More days of PS are perceived by
members of the public to have an increasing negative
impact on HRQoL. Therapies aimed at reducing the
number of days on PS may be beneﬁcial for improving
patients' HRQoL. (Clin Ther. 2018;40:1878e1893) ©
2018 The Authors. Published by Elsevier Inc. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Key words: intestinal failure, parenteral support,
short bowel syndrome, utility study, United Kingdom.
INTRODUCTION
Intestinal failure (IF) has been deﬁned as “the reduction of
gut function below the minimum necessary for the
absorption of macronutrients and/or water and
electrolytes, such that intravenous supplementation is
required to maintain health and/or growth.”1 IF is
reﬁned into 3 categories: type 1, acute; type 2, prolonged
acute; and type 3, chronic.2 The most frequent
mechanism of IF is short bowel syndrome (SBS) in which
functional small intestine length is typically <200 cm3
and is the result of an intestinal resection. The
prevalence of SBS in Europe is estimated at 1.4 per
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million, although it is recognized to vary widely, from 0.4
per million in Poland to 30 per million in Denmark, and
these variations may be due to differences in the
availability of intestinal rehabilitation centers.4
The causes of SBS in adults are most frequently
mesenteric ischemia and Crohn's disease.5 SBS can be
categorized according to anatomy and pathophysiologic
consequences (eg, without colon in continuity).3
Patients with SBS frequently experience debilitating
symptoms associated with their underlying condition,
including weight loss, lethargy, diarrhea, excessive
stoma losses, dehydration, incontinence, stoma leakage,
and abdominal pain.6
Treatment of chronic IF requires complex technologies
along with multidisciplinary input and expertise,3 of
which home-based intravenous supplementation (called
parenteral support [PS] or parenteral nutrition) is a
central component. The speciﬁc components of PS will
vary according to the individual patient's macronutrient,
micronutrient, and ﬂuid requirements. PS is administered
intravenously into a central venous catheter.7 Individuals
with chronic or type 3 IF2 can be trained to self-
administer PS at home, usually overnight.7 When this
approach is not possible, a carer, family member, or
home care nurse can administer PS. The levels of speciﬁc
nutrients and ﬂuid volumes needed by individual
patients are based on a formal nutrition and ﬂuid
balance assessment and are primarily determined by the
length of residual healthy small bowel and the presence
of disease in the remnant small bowel that may further
impair absorption; thus, individuals with less small
bowel remaining tend to need more PS administered
over an increasing number of nights per week.3
It is established that patientswith SBS-IF have a reduced
health-related quality of life (HRQoL) as a result of their
underlying condition and need for PS.8,9 Furthermore,
the need for long-term PS can lead to morbidity and,
occasionally, mortality, as a result of complications
related to the central venous catheter (eg, infections and/
or thrombosis), liver disease, dehydration, and renal
failure.7 These complications can lead to recurrent
hospital admissions, further affecting an individual's
HRQoL and overall anxiety related to their
condition.7e9 Overall, however, home PS offers life-
saving therapyand theability to receive treatment at home.
Novel therapeutic options have been developed
recently to reduce or even obviate PS requirements in
SBS-IF; these options include surgical procedures such
as transplantation and small bowel lengthening, as
well as medical therapies aimed at improving the
absorptive capacity of the residual small bowel.7 Of
the latter, a long-acting analogue of glucagon-like
peptide 2 (teduglutide) has been shown in recent
studies to reduce PS requirements in individuals with
SBS-IF.10 Cost-effectiveness analyses of such therapies
are required to inform resource allocation decisions
in health care.11 Economic-related studies include the
development of an algorithm by which to estimate
utility scores from a patient-completed SBS-quality of
life measure (SBS-QoL),12 home- versus hospital-
administered PS,13 parenteral and enteral route of
administration,14 and collection of utility values
associated with PS in Canadian patients with SBS.15
Ideally, utilities would be obtained directly from
patients by using measures such as the Euro-QoL 5D
descriptive system (EQ-5D). SBS-QoL patient data
from clinical trials could also provide utilities when
using the published algorithm.12 However, it would
be very challenging to capture sufﬁcient data to
describe the nature of every model state when
assessing the number of days on PS, especially given
the rarity of the disease. The aims of the present
study were as follows: ﬁrst, to develop bespoke
health state vignette descriptions of states for
numbers of days on PS in SBS; and second, to obtain
UK utility weights for these health states by using a
time trade-off (TTO) preference elicitation technique.
PATIENTS AND METHODS
Study Design
Evaluation of cost-effectiveness is commonly
assessed in terms of quality-adjusted life years, which
are the product of HRQoL and survival. In the
United Kingdom, the National Institute for Health
and Care Excellence recommends that HRQoL be
expressed as a preference-weighted index, preferably
using the EQ-5D.16 However, EQ-5D data were not
available to assess utilities associated with PS and
SBS health states. This study was designed to capture
HRQoL weights (utilities) for estimating quality-
adjusted life years associated with PS in SBS and to
meet the requirements of health technology
assessments as far as possible (eg, as discussed by the
National Institute for Health and Care Excellence17).
Health states (vignettes) were ﬁrst developed by
using recognized methods18 and are described in the
following sections. The valuation sample comprised a
convenience sample of 100 adults of the general
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public in the United Kingdom who completed a TTO-
based valuation exercise to elicit utility values for the 8
health state vignettes. A sample of 100 participants
provides 100 ratings and 100 valuations for each of
the 8 health states. An overview of the methods is
provided in Figure 1.
Health State Development
Health states were developed from 3 sources: a
literature review and interviews with patients and
health care professionals (HCPs).
Targeted Literature Review
A targeted literature review was undertaken to
identify the impact of SBS on patients' HRQoL. This
review comprised a search in EMBASE and
MEDLINE for English language articles published in
the last 10 years (conducted July 2015). Key words
included quality of life, coping, short bowel syndrome,
and other related terms (see Supplemental Material
Tables 1 and 2 in the online version at doi:10.1016/
j.clinthera.2018.09.009). Searches yielded 241 hits,
with an additional 2 hits derived from Google Scholar.
After excluding duplicates, 170 abstracts were
reviewed for eligibility; studies that referred to QoL or
EQ-5D domains were included, and pediatric studies
were excluded. Twelve studies met the inclusion
criteria, and the full-text articles were retrieved. Three
of these articles were excluded after full article review
because they were considered insufﬁciently relevant:
one related to algorithm development,12 and two
related to the development of instruments to assess
home PS19 and pump types.20 Figure 2 presents a
description of the literature review process.
The remaining articles provided useful information
regarding the burden of SBS and PS. Studies
highlighted the impact of home PS; that is, it
provided energy for daily activities but patients were
also affected by length of infusion schedules,21 with
night infusions potentially disrupting sleep.22 Studies
outlined the burden of symptoms such as severity of
gastrointestinal symptoms, fatigue, and diarrhea,21
complications of PS,23 and that patients with SBS had
more severe fatigue and symptom severity compared
with patients with inﬂammatory bowel disease.24
Studies identiﬁed the psychosocial burden, including
worry about the risk of catheter-related infections,
general emotional problems, and disruption to social
activities.23,25e27 Compared with ﬁndings from the
general population, HRQoL was impaired on most
of the 8 domains of the 36-Item Short Form Health
Survey questionnaire (in 6 dimensions24 and 7
dimensions28). Affected domains of HRQoL are
reﬂected in an article outlining the SBS-QoL measure:
general well-being, everyday activities, working-life,
Targeted literature review to inform health 
states
Exploratory interviews to inform health 
states
 Semi-structured interviews with clinicians (n = 4)
 Patients with short bowel syndrome and parenteral support 
interviews (n = 12)
Draft health states developed
 Reviewed by clinician/nurses (n = 3) to ensure accuracy
 Reviewed by scientific advisors (n = 2) for likelihood of 
acceptability by health technology assessment body
Piloting of health states
 Cogntitive debrief interviews conducted with members of the
UK general public (n = 5) 
Time trade-off interviews
 Interviews completed with members of the UK general public 
(n = 100)
Time trade-off data analyzed
Figure 1. Overview of study methods.
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leisure activities, social life, energy level, physical
health, mobility and self-care activities, pain, diet,
eating and drinking habits, emotional life, sleep,
gastrointestinal symptoms, fatigue and weakness,
diarrhea, skeleton and muscle symptoms, discomfort
and other symptoms.6
Patient Interviews
Patients from a patient support group were asked to
comment on an interview guide developed for this
study to help ensure that language was appropriate
for the patient population. Patients with SBS and
currently receiving home PS were then recruited from
an outpatient clinic in the United Kingdom. All
procedures were performed in accordance with the
ethical standards of the national research committee
(for patients recruited at clinic, reference no. 15/NW/
0576). Informed consent was obtained in writing
from all individual participants included in the study.
An invitation letter was sent to patients before their
appointment, and they were asked at the clinic if they
wished to participate. If they were amenable, written
consent was recorded by a clinician. A purposive
sampling procedure was used to obtain a cross-
section of the population including patients of
different ages, sex, duration, and number of nights
on PS (such as that described by Fade and Swift29).
Twelve patients completed in-person interviews
with an interviewer using a semi-structured interview
schedule. These interviews were transcribed verbatim,
and coding was managed by using Atlas.Ti scientiﬁc
software version 7 (ATLAS.ti Scientiﬁc Software
Development GmbH, Berlin, Germany; 2013). A
thematic approach to analysis was undertaken and
N
(MEDLINE, n = 88; EMBASE, n = 153)
n
n n
n
n
n
N = 2
Figure 2. Description of literature review process.
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focused on patients' experience of SBS and PS and the
impact on their daily lives. Data from the patient
interviews will not be made available.
HCP Interviews
HCPs who regularly worked with UK patients with
SBS were invited to take part in a telephone interview
(the authors of the present article were not
interviewed). Four interviews were conducted using a
semi-structured interview guide. These were audio
recorded, and written summaries were produced. The
aim of the ﬁrst 2 interviews was to understand the
burden of SBS on patients; the aim of the third and
fourth interviews was to understand how HRQoL
was related to the number of days on PS.
Draft Health State Development
Information from the literature review and patient
and HCP interviews were used to develop the ﬁrst
draft of the health state vignettes. These health states
included 8 attributes. The ﬁrst 3 described the
condition, symptoms, and treatment. The next 5
attributes described the typical HRQoL effects of a
person with SBS in the 5 EQ-5D domains (mobility,
self-care, usual activities, pain or discomfort, anxiety,
or depression). These were structured on the EQ-5D
format to maintain some consistency with the
preferred instrument of the National Institute for
Health and Care Excellence.17 Eight health states
corresponded to 0 days on PS (having been weaned
off PS) and 1 to 7 days of PS per week. Because the
focus was on the number of days of PS, it was
decided that health states should exclude speciﬁc
reference to stoma use.
Draft Health State Review
The ﬁrst draft health states were reviewed by 3
HCPs for accuracy and clinical validity during
telephone interviews. These interviews were
conducted with 2 clinicians who took part in the
earlier interviews and an experienced nurse who was
not previously interviewed, and who had particular
experience with patients on fewer days of PS. These
interviews were audio-recorded and summarized.
The HCPs generally believed that the draft health
states characterized the impact of SBS on HRQoL
and made some minor suggestions to help improve
their accuracy. They appreciated the need to present
a “typical patient” when in actuality there is
underlying variability in conditions leading to SBS
and the variations in types of PS needed. Views
varied regarding the duration of PS administration;
thus, due to the nurse's greater experience with the
patients on fewer days PS and for methodologic
reasons (ie, comparison between states not being
affected by length of time on PS), it was agreed to
have consistent description of 10 to 14 hours across
all days on PS. This range of hours was agreed to be
a reasonable average across patients with SBS.
Cognitive Interviews of Health States
Following the health state revisions, the second
version of the health states was assessed via cognitive
interviews with 5 members of the general public. All
procedures were performed in accordance with the
1964 Helsinki declaration and its later amendments
or comparable ethical standards. Informed consent
was obtained in writing from all individual
participants included in the study. The aim of these
face-to-face interviews was to assess the interpretation
of the concepts, comprehension of wording, and
rating of the health states using the EQ-5D visual
analog scale (VAS). Participants were also asked for
general comments and any areas for improvement.
The sample comprised 3 male subjects and 2 female
subjects, aged 25 to 66 years (mean age, 52 years),
and their own health was rated on the EQ-5D VAS at
a mean of 86 (range, 70e100). The concepts and
health states were found to be easily understood by
all participants, and 2 participants suggested minor
changes (eg, the term “irresistible” for toilet urgency
was dropped; and a suggestion to replace “need to
urinate” with “need to go to the bathroom” was not
replaced because of the need to be speciﬁc about this
aspect of the condition). The draft health states were
all assigned decreased VAS scores as the number of
days on PS increased, indicating that severity had
been appropriately understood.
Final Health States
The third version of the health states was reviewed
and agreed to by the study team and expert
consultants (excluding the clinical authors of the
present article) to ensure they were ﬁt for purpose.
The ﬁnal 8 health states for inclusion in the study
were 0 days on PS (weaned off), and each of 1 to 7
days on PS per week. These were used alongside
descriptions of full health and dead states.
Clinical Therapeutics
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The draft health state vignettes were developed to
provide a general description of the HRQoL of a
person with SBS in the speciﬁc state relating to
number of days on PS and speciﬁcally for use in
economic modeling. Given the underlying variability
in conditions leading to SBS and the variations in
types of PS needed, these health states are inevitably
a simpliﬁcation, and some aspects will not apply to
all patients. When the states were presented to lay
members of the general public for valuation, they
were not told the name of the disease. Table I
presents a summary of the states.
Health State Valuation
Sample and Eligibility
A convenience sample of 100 members of the UK
general public was recruited by interviewers to
participate in the valuation exercise to elicit utility
values for the 8 SBS health states. This exercise
comprised a face-to-face interview lasting up to 1 hour
using the TTO preference elicitation technique
(described in the section that follows). The inclusion
criteria for recruits were age 18 years, current resident
in the United Kingdom, able to understand the survey
as judged by the investigator, and able to give informed
consent. Exclusion criteria included presence of an
acute illness or cognitive impairment that in the opinion
of the investigator would interfere with the study
requirements and an inability to provide informed
consent.
Four trained ﬁeld interviewers based in different UK
locations (Bristol, Warwickshire, and London)
recruited participants with the aim to reﬂect age and
ethnic diversity. Study details were given to potential
participants. All procedures were performed in
accordance with the 1964 Helsinki declaration and
its later amendments or comparable ethical
standards. Willing individuals provided written
informed consent before data collection, and they
were reimbursed for their time (£25 per individual).
Procedures
The following data collection procedures were
undertaken. First, participants completed a
sociodemographic form (eg, age, sex, education).
Second, participants completed the 5-level EQ-5D
instrument, including the visual analog question asking
for rating of their health.30 Third, participants rated the
SBS PS health states using the VAS. Each of the 8 health
states were printed on individual cards (along with full
health and dead states). The name of the health states
had been replaced with a symbol to avoid any reference
to the condition. Using an enlarged copy of the EQ-5D
VAS scale, participants were presented with 1 health
state at a time in a random order and asked to rate each
of the health state vignettes. This task was designed to
familiarize participants with the health states vignettes.
Participants placed the cards on a 100-point VAS
according to their opinion. A rating of 100 was deﬁned
to participants as “the best possible state of health
imaginable.” The values given to each health state were
documented, and participants were given the option to
revise the values at the end of the exercise.
Finally, participants provided ratings for each of the
8 health states using the TTO technique and a standard
prop. Here, the same health state cards were presented
in a random order. Randomization of states follows
recommended procedures and reinforces the validity
of results (eg, any trend is in spite of the sequence of
administration).31 For states regarded as better than
being dead, respondents were presented with a series
of pairwise choices and asked to choose between
living in the health state for 10 years or living in a
state of full health for 10 years. Time in full health
was varied in 6-month increments until the
participant was indifferent between the 2 choices.
The amount of time in the state that someone is
willing to trade is taken to indicate the value or
utility of the state. The TTO method, in deriving
utility values based upon subjects' responses to
decision scenarios, was speciﬁcally developed for use
in health care.32 A 10-year time horizon was selected
to provide a consistent time frame for all respondents
and has been commonly used in previous studies in
line with initial EQ-5D valuation work33; it does not
reﬂect life expectancy associated with SBS or PS (for
which life expectancy is principally determined by the
disease underlying SBS). Any states that were valued
as worse than dead were valued by using Lead-Time
methods using a standard lead-time TTO (LT-TTO)
board. LT-TTO is another variant of TTO in which
each option has an additional 10 years in full health
at the start before proceeding to the 10 years in the
ill health state or 10 years in full health. This
method allows for utility scores of between 0 and e1
to be elicited.34 An alternative to LT-TTO was
previously used comprising 2 tasks: one for states
R. Ballinger et al.
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Table I. Final health state categories.
1. Condition description  Full health: You do not have any illnesses
 0 days on PS (weaned off): You have a condition where you need to pay
attention to your ﬂuid and nutrient intake
 1e7 days on PS: You have a condition where you need to pay attention
to your ﬂuid and nutrient intake and cannot absorb nutrients normally
2. Symptom description  0 days on PS (weaned off): You may feel dehydrated, weak, and tired. You
sometimes have diarrhea and a sudden need to have a bowel movement
 1e3 days on PS: (as per 0 days) and you have to limit your food and drink
intake*
 4e7 days on PS: (as per 1e3 days) and minor change from “you sometimes
have diarrhea” to “you have diarrhea”
3. Treatment description  Full health: You are not receiving any treatments
 0 days on PS (weaned off): You take medication to treat your diarrhea.
You have a daily allowance in the amount you can drink. You have a diet that
needs to be high in fat.y Sometimes you need to drink I L of a glucose-saline
drink, which tastes a bit like seawater
 1e7 days on PS: You are administered nutrient solution through a tube in your
chest for 10e14 hours on [number] days a week. This supplements the
food and drink that you eat normally
4. Mobility  Full health: You have no physical problems walking about
 0 days (weaned off)e7 days on PS: You have no physical problems walking about
5. Self-care  Full health: You have no problems washing and dressing yourself
 0 days on PS (weaned off): You have no problems washing and dressing
yourself
 1e7 days on PS: (in addition to 0 days) you need to be cautious when
washing yourself to minimize risk of infection to your tube. You need to
get up in the night to urinate on your [number] days of treatment
6. Usual activities  Full health: You have no problems in completing your usual activities
 0 days on PS (weaned off): Due to diarrhea and fatigue, you are
sometimes limited in your usual activities
 1e3 days on PS: (in addition to 0 days) and due to having a tube, you are
unable to do physical exercise.z Due to time for medical care, you are
sometimes limited in your daily activities on your [number] days of
treatment
 4e5 days on PS: (as per 1e3 days) and minor change from “you are
sometimes limited” to “you are limited in your daily activities on your
[number] days of treatment”
 6e7 days on PS: (as per 4e5 days) and it is difﬁcult to take part in
spontaneous activities
7. Pain/discomfort  Full health: You have no pain or discomfort
 0 days (weaned off)e7 days on PS: You have pain if you eat ﬁbrous
food
8. Anxiety/depression  Full health: You are not anxious or depressed
 0 days on PS (weaned off): You are glad that you do not need to receive
nutrients through a tube in your chest
(continued on next page)
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better than dead and another for states worse than
dead. This approach has been shown to result in a
discontinuity of values and 2 very different
distributions of values, raising doubts about whether
they can be regarded as being on the same scale.34
The LT-TTO approach was therefore used because it
provides the respondent with more years to use up
and means that there is only 1 TTO task, reducing
the risk of confusion.
Data Entry and Analysis
Interviewers entered the data onto a pre-prepared
Excel spreadsheet (Microsoft Corporation, Redmond,
Washington). Fifty percent of data entry was double-
checked to verify the database before analysis (within
each of the datasets provided by the 4 interviewers,
data for veriﬁcation was randomly selected). The
utility interview data will be shared with researchers
upon request. Basic descriptive analysis was
undertaken using Excel to describe the study sample
and for comparison versus Ofﬁce of National
Statistics published norms35e37; comparison of their
health status according to the EQ-5D versus UK
published norms38; and to report the VAS ratings of
health states (range, means, and SDs) and TTO
values of health states (range, means, and SDs).
Analysis was conﬁrmed independently by a second
member of the study team by review of Excel
analysis codes and results. Linear regression analyses
of VAS ratings and utility scores against health states
were conducted in Stata version 12.1 (StataCorp,
College Station, Texas). Separate models were run
with health states as a continuous variable (in terms
of the number of days receiving PS) and as dummy
variables.
RESULTS
Participant Characteristics
Table II displays the sample characteristics of the
100 members of the UK general public who were
interviewed and comparative data from the Ofﬁce of
National Statistics for a UK population.
Table III details the EQ-5D dimension reported by the
study sample and theUKnorms.38Overall, the differences
were modest, although the study sample reported fewer
problems than the UK general public. The sequence of
most affected domains was the same: pain or discomfort
had the greatest proportion, followed by anxiety or
depression, mobility, and usual activities, with self-care
the least affected. The mean state of health recorded on
the VAS was similar to UK norms (83.25 with standard
deviation of 15, vs. 82.5 with standard deviation of 17)
[38].
VAS Ratings of Health States
Table IV shows the mean scores from the VAS
ratings of the health states, which had been
administered in random order. The highest mean
Table I (continued)
 1e5 days on PS: You sometimes worry about getting an infection and
your long-term health. You feel anxious in case you need to get to a toilet
quickly. You sometimes feel your treatment is a bit difﬁcult to cope with
 6 days on PS: (as per 1e5 days) and you value having 1 day per week
without having treatment
 7 days on PS: (as per 1e5 days) and you would value having 1 day per week
without having treatment
Dead state  You are dead
PS ¼ parenteral support.
* Patients with short bowel syndrome (SBS) often have to follow a special diet, and thus “limit” is intended here to broadly refer
to constraints rather than to quantity, per se.
y SBS can include patients with a colon in continuity. Such patients are advised not to have a diet high in fat.
zThis should not be taken to imply that SBS patients receiving PS are unable to exercise, although they are limited during the
time they are connected to PS. Patients’ general ability to exercise are more likely to be associated with the conditions
underlying SBS, and any concerns that patients might have about this topic should be discussed with their health care
professional.
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Table II. Participant characteristics.
Characteristic N ¼ 100 Population*
Sex
Male 33 (33%) 31,793,606 (49.2%)
Female 67 (67%) 32,803,146 (50.8%)
Age, y
Median (mean [SD]) 32 (38.04 [15.84]) 40
Range 18e87 e
Ethnicityy
White, Britishz 75 (75%) 80.5%
White, other 6 (6%) 5.4%x
Asian/Asian Britishk 8 (8%) 6.0%
Black British/African/Caribbean/
black, Caribbean
4 (4%) 1.1%
Mixed/multiple ethnic group¶ 7 (7%) 1.9%
Main activity#
Employed 79 (79%; of which
17% are part-time)
74%**
Student 11 (11%) e
Unemployed 3 (3%) 5.1%
Retired 7 (7%) 13.1%
Self-employed 1 (1%) e
Qualiﬁcations
No formal qualiﬁcations 2 (2%) 22.7%
GCSE/secondary school 8 (8%) 28.6%yy
A Levels/college 24 (24%) 15.9%zz
Undergraduate degree (BSc, BA) 36 (36%) 27.2xx
Postgraduate degree (e.g. masters’, PhD) 29 (29%) e
Other 1 (1%) 5.7
Marital status
Single 40 (40%) 34.6%
Partnership 23 (23%) 0.2%kk
Married 29 (29%) 46.6%
Divorced/separated 6 (6%) 11.6%
Widowed 1 (1%) 7%
Other 1 (1%) e
GCSE ¼ General Certiﬁcate of Secondary Education; A Level ¼ General Certiﬁcate of Education Advanced Level;
BSc ¼ Bachelor of Science; BA ¼ Bachelor of Arts; PhD ¼ Doctor of Philosophy.
* Ethnicity, qualiﬁcations, and marital status data from England and Wales Census data (Ofﬁce for National Statistics, 2011).35
Sex and age data from Overview of the United Kingdom (Ofﬁce for National Statistics, 2015).36 Employment data from UK
Statistical Bulletin (Ofﬁce for National Statistics, 2015).37
yOfﬁce of National Statistics (ONS) percentages calculated from equivalent categories as per footnotes z through ¶.
zWhite, British calculated by combining: white, English; white, Welsh; white, Scottish; and white, Northern Irish.
xCalculated from the ONS groups: white, Irish; white, Gypsy or Irish Traveller; white, other white.
kAsian/Asian British group calculated by combining: Asian/Asian British, Indian; Asian/Asian British, Pakistani; Asian/Asian
British, Bangladeshi; and Asian/Asian British, Chinese.
¶Mixed/multiple ethnic group calculated by combining: mixed/multiple ethnic group, white and black Caribbean; mixed/
multiple ethnic group, white and Asian; and mixed/multiple ethnic group, other.
#One participant responded that they were both employed full-time and a student.
** People aged 16 to 64 years, part-time and full-time combined, students in employment included.
yy Level 1 (1e4 GCSEs or equivalent) and Level 2 (5 GCSEs or equivalent) qualiﬁcations combined.
zzApprenticeships and Level 3 (2 + A Levels or equivalent) qualiﬁcations combined.
xx Level 4 qualiﬁcations or above (bachelor's degree or equivalent, and higher qualiﬁcations).
kkRegistered same-sex civil partnership (there is no other partnership category in ONS; anyone not married but living with a
partner would possibly be considered “single”).
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(SD) value is for the 0 days on PS at 0.70 (16), with the
lowest value for 7 days on PS at 0.26 (18). The ratings
of the health states show a decline according to number
of days on PS. The largest decline between the mean
ratings of consecutive states was from 0 days
(weaned off) to 1 day (declined by 0.13). The decline
in mean ratings between the other consecutive states
ranged from 4 to 7 points.
The results of the regression models of VAS ratings
of health states, predicted by health states in terms of
number of days receiving PS as a continuous variable
and as dummy variables, are shown in Tables V
and VI, respectively. The continuous variable model
showed a signiﬁcant difference in VAS ratings across
the health states, whereby for every 1 additional day
receiving PS there was an estimated 5.96-point
reduction in VAS ratings (P < 0.001). The ﬁndings
from the dummy variable model are in agreement:
relative to zero days, all other numbers of days
receiving PS are associated with signiﬁcant reductions
in VAS ratings (−13.79 [1 day] to −44.81 [7 days];
P < 0.001). There is limited literature by which to
Table III. Comparison of health status of the study sample versus UK published norms according to EuroQol-5
dimensions.
Dimension Study Sample* (N ¼ 100) UK Normsy (N ¼ 3395)
Any Problem % Ranking Any Problem % Ranking
Mobility 14 3 18.4 3
Self-care 2 5 4.2 5
Usual activities 13 4 16.3 4
Pain/discomfort 27 1 33.0 1
Anxiety/depression 19 2 20.9 2
Any dimensions 36 43.1
* Study sample using the 5-level EuroQoL 5 dimension.
yUK norms using the 3-level EuroQoL 5 dimension.
Table IV. Visual analog scale rating of health states (with full health at score 100) (N ¼ 100).
Health State Mean (SD) Difference Between
Consecutive States
Minimum
Rating Given
Maximum
Rating Given
0 days on PS
(weaned off)
0.70 (0.16) 8 95
1 day on PS 0.57 (0.17) 0.13 12 90
2 days on PS 0.50 (0.17) 0.07 5 90
3 days on PS 0.45 (0.18) 0.05 3 95
4 days on PS 0.39 (0.17) 0.06 2 80
5 days on PS 0.35 (0.18) 0.04 0* 95
6 days on PS 0.30 (0.18) 0.05 0y 90
7 days on PS 0.26 (0.18) 0.04 0z 90
PS ¼ parenteral support.
*One participant rated 5 days on PS as equal to death.
y Four participants rated 6 days on PS as equal (n ¼ 3) or worse (n ¼ 1) than death.
z Seven participants rated 7 days on PS as equal (n ¼ 4) or worse (n ¼ 3) than death.
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assess meaningful change in VAS ratings. One study
using a respiratory questionnaire and a feeling
thermometer VAS suggests that a change of 5 to 8
points out of 100 could be taken to be clinically
important in patients.39 Although not strictly
comparable with members of the public, this ﬁnding
could nonetheless provide some indication that the
VAS reductions are meaningful.
Health States Utility Scores
Table VII presents the results of the mean TTO
utility values elicited for each of the 8 health states
(these were administered in random order in
interviews). The highest mean (SD) value is for the
0 days on PS (0.82 [0.22]), with the lowest value for
the state 7 days on PS (0.36 [0.35]). The ratings of
the health states show a decline by number of days
on PS. However, the largest decline was between 5
days to 6 days on PS (declined by 0.10), which is
different from the largest decline by ratings using the
VAS (as reported above, this was 0e1 days). The
decline in mean utilities between the other
consecutive states ranged from a difference of 0.04 to
0.07. In the wider literature, a difference or change
of 0.05 has been used as a guideline for clinically
important difference in TTO scores.40,41 This
outcome, then, would suggest that all changes, apart
from 0 days to 1 day on PS, could be considered
meaningful, albeit based on group mean scores
provided by members of the public. Three
participants valued one or more health states as
worse than death.
The results of the regression models of utility scores,
predicted by health states in terms of number of days
receiving PS as a continuous variable and as dummy
variables, are shown in Tables VIII and IX, respectively.
The continuous variable model shows that the number
of days receiving PS is signiﬁcantly associated with utility
scores. For every 1 additional day receiving PS, there is
an estimated 0.07 reduction in utility scores (P < 0.001).
Table V. Results of simple linear regression models of visual analog scale ratings of health states against the
number of days receiving parenteral support (PS) of the health state (as a continuous variable).
Model Regression Estimates
Beta-Coefﬁcient (SE) CI P
Days on PS −5.96 (0.27) −6.49 to −5.44 <0.001
Intercept 64.85 (1.12) 62.64 to 67.05 <0.001
Table VI. Results of multiple linear regression models of visual analog scale ratings of health states against the
number of days receiving parenteral support (PS) of the health state (as dummy variables; reference
group ¼ 0 days on PS).
Model Regression Estimates
Beta-Coefﬁcient (SE) CI P
0 days on PS (weaned off) Ref Ref Ref
1 day on PS −13.79 (2.44) −18.59 to −8.99 <0.001
2 days on PS −20.03 (2.44) −24.83 to −15.23 <0.001
3 days on PS −25.69 (2.44) −30.49 to −20.89 <0.001
4 days on PS −31.26 (2.44) −36.06 to −26.46 <0.001
5 days on PS −35.62 (2.44) −40.42 to −30.82 <0.001
6 days on PS −40.77 (2.44) −45.57 to −35.97 <0.001
7 days on PS −44.81 (2.44) −49.61 to −40.02 <0.001
Intercept 70.47 (1.73) 67.08 to 73.86 <0.001
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Table VII. Health states utility scores (N ¼ 100).
Health State Mean (SD) Change Between
Consecutive
States
Minimum
Rating Given
Maximum
Rating Given
No. of Participants
Valuing State
Worse Than Death
0 days on PS
(weaned off)
0.82 (0.22) −0.48* 1 1
1 day on PS 0.78 (0.23) 0.04 −0.48 1 1
2 days on PS 0.72 (0.23) 0.06 −0.48 1 1
3 days on PS 0.65 (0.27) 0.07 −1 0.98 1
4 days on PS 0.58 (0.31) 0.07 −1 1 2
5 days on PS 0.51 (0.33) 0.07 −1 0.98 2
6 days on PS 0.41 (0.34) 0.10 −1 0.98 3
7 days on PS 0.36 (0.35) 0.05 −1 1 2
PS ¼ parenteral support.
*One participant rated all states, including 0 days, as worse than death. Also, 3 participants rated all health states the same
(each valued all health states at 0.98).
Table VIII. Results of simple linear regression models of utility scores for the health states against the number of
days receiving parenteral support (PS) of the health state (as a continuous variable).
Model Regression Estimates
Beta-Coefﬁcient (SE) CI P
Days on PS −0.07 (0.004) −0.08 to −0.06 <0.001
Intercept 0.84 (0.02) 0.81 to 0.88 <0.001
Table IX. Results of multiple linear regression models of utility scores for the health states against the number of
days receiving parenteral support (PS) of the health state (as dummy variables; reference group ¼ 0
days on PS).
Model Regression Estimates
Beta-Coefﬁcient (SE) CI P
0 days on PS (weaned off) Ref Ref Ref
1 day on PS −0.04 (0.04) −0.12 to 0.04 0.286
2 days on PS −0.10 (0.04) −0.18 to −0.02 0.013
3 days on PS 0.17 (0.04) −0.25 to −0.09 <0.001
4 days on PS −0.24 (0.04) −0.32 to −0.16 <0.001
5 days on PS −0.32 (0.04) −0.40 to −0.23 <0.001
6 days on PS −0.41 (0.04) −0.49 to −0.33 <0.001
7 days on PS −0.46 (0.04) −0.54 to −0.38 <0.001
Intercept 0.82 (0.03) 0.76 to 0.88 <0.001
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The dummy variable model estimates that relative to zero
days,2 days showa signiﬁcant reduction in utility scores
(−0.10 [2days] to−0.46 [7days];P<0.013).Therewasno
signiﬁcant difference betweenutility scores for 0 and 1day
receiving PS (P ¼ 0.286).
DISCUSSION
To the best of our knowledge, this study is the ﬁrst to
show that utilities are perceived by the general public
to be associated with different levels of PS on the
HRQoL of individuals with SBS in the United
Kingdom. Signiﬁcantly, the study reported a decline
in utility values measured by TTO with increased
number of days on PS, with 7 days on PS showing
the largest disutility and 0 days on PS the smallest
disutility from full health. Decline in TTO utility
values was conﬁrmed by a corresponding decline in
the health states rating by using the VAS and in the
regression analyses undertaken. When using dummy
variables, the utility scores only exhibited a
signiﬁcant reduction with each additional day of PS
from 2 days or more. These data suggest that any
treatment which may help reduce the number of days
on PS could be seen as beneﬁcial for the HRQoL of
patients with SBS receiving PS and may be used to
assess cost-effectiveness of such a treatment.
This monotonic decline is similarly reﬂected in a
Canadian utility study.15 In that study, 799 valid
respondents (of 1277 participants) evaluated 3 health
states each by a web-based TTO study. These states
were similarly deﬁned by numbers of days on PS
(0e7 days), with the 7 days on PS divided into low
and high liter amounts of PS administered. The
largest disutility was 7 days on PS high liter volume
valued at 0.39, with the smallest disutility being
0 days on PS at 0.74. Thus, despite the differences in
methods, the ﬁndings from the Canadian study were
broadly in keeping with the present UK study. The
UK study shows this relationship is monotonic across
the range of PS, which has important implications for
the beneﬁts of interventions.
There are study limitations that should be
considered. First, the TTO study sample was
younger, with more female subjects, and 9% more
had an undergraduate degree compared with the
general UK population. However, the ethnicity,
qualiﬁcations, and marital status data came from a
2011 census that may have changed since that time.
The modestly better health of the sample according
to EQ-5D scores may reﬂect the slightly younger
study population compared with general population
norms. Second, the 10-year time horizon does not
reﬂect any speciﬁc life expectancy associated with PS
and SBS because of the heterogeneity of the
conditions underlying SBS. Nonetheless, compared
with longer time horizons, 10-year horizons could
result in higher or less conservative utility values
because of increased loss aversion to the amount of
time traded off.42,43 There is no apparent consensus
in the literature about the right time horizon for
health states. Although states could have been valued
differently with a different time horizon in this study,
it may be reasonable to consider that the relative
differences between the states are unlikely to change.
A vignette approach has previously been criticized
because the content is often not empirically
determined with input from patients and clinicians
and is not usually formally validated.18 If the vignettes
are poorly designed, they can lead participants to
focus on very speciﬁc aspects of HRQoL, which can
cause exaggerated differences in the resulting utilities.
However, this study undertook several steps to ensure
robust vignette development in the drafting, review,
and ﬁnalization. The symptoms described were those
reported for a “typical” patient; however, it was clear
from the literature review and patient and HCP
interviews, that there is no such thing as a typical SBS
patient, because of the underlying heterogeneity of
conditions and differences in nutritional requirements.
More states could have been valued to have allowed
for such heterogeneity. As it was, we attempted to
keep health state descriptions as simple as possible. In
addition, because of recruitment difﬁculties, no
interviews were conducted with patients who had
been weaned off or received only 1 or 2 days of PS.
Therefore, the vignettes corresponding to these health
states relied upon data from the literature review and
HCP interviews only. There is some literature
showing discordance between patient and HCP
perceptions in other conditions and clinical
contexts,44e48 and thus it is possible that patients
with SBS who had been weaned off PS or had
received only 1 or 2 days of PS may have different
views than the information provided in the literature
or HCP interviews. Furthermore, in the absence of
direct experience with new therapies that may help
maintain a patient's nutritional balance while reducing
the need for PS, it is possible that patients may feel
Clinical Therapeutics
1890 Volume 40 Number 11
reassured by continued PS knowing their nutritional
requirements are being met. Review of draft health
states was conducted with HCPs and members of the
public, but it may have been useful to have included
patients. Finally, participants may have made
assumptions about the condition and treatment
beyond the information that was provided in the
vignettes, which could inﬂuence their responses (eg,
how having a tube in their chest might feel and affect
daily activities). However, the participants in the
cognitive interviews were speciﬁcally asked if there
were any ways in which the health states could be
improved, and none indicated need for additional
information. Furthermore, it is not common practice
to assess how participants reach their judgments when
providing their responses during TTO interviews.
CONCLUSIONS
This study has produced utility weights from a UK
general population sample for states associated with
PS in SBS and, to do so, used a robust approach to
vignette development. The ﬁndings show how utility
values were progressively worse as the number of
days on PS increased.
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APPENDIX A. SUPPLEMENTARY DATA
Supplementary Material Table 1. Search strategy in
Embase
Database: Embase <1974 to 30 June 2015>
1 QOL.tw. (39442)
2 (value adj2 life).tw. (749)
3 “Value of Life”/ (116895)
4 “Quality of Life”/ (287073)
5 Quality of Life.tw. (249117)
6 life quality.tw. (7506)
7 HRQL.tw. (3760)
8 HRQoL.tw. (13351)
9 health related quality of life.tw. (34461)
10 patient$ attitude$.tw. (2741)
11 patient attitude/ (51425)
12 attitude to health/ (86802)
13 (attitude adj3 health).tw. (1227)
14 well$ being.tw. (55897)
15 wellbeing/ (37644)
16 cost of illness/ (15556)
17 Emotion/ (78073)
18 (burden adj3 (illness
or disease$)).tw.
(24696)
19 coping behavior/ (38338)
20 (cope or coping).tw. (71742)
21 (value adj2 life).tw. (749)
22 psychological$ adapt$.tw. (663)
23 (psychological$ adj3 adapt$).tw. (1175)
24 or/1e23 (792065)
25 short bowel syndrome$1.tw. (3205)
26 short gut syndrome$1.tw. (365)
27 short intestinal syndrome$1.tw. (3)
28 short intestine syndrome$1.tw. (35)
29 chronic intestinal failure.tw. (111)
30 if type 3.tw. (4)
31 if type iii.tw. (5)
32 short bowel syndrome/ (4356)
33 or/25e32 (5103)
34 24 and 33 (357)
35 limit 34 to (English language
and last 10 years)
(191)
36 conference.so. (1926416)
37 35 not 36 (153)
Supplementary Material Table 2. Search strategy in
Medline
Database: Ovid MEDLINE
®
In-Process &
Other Non-Indexed Citations and Ovid
MEDLINE
®
<1946 to Present> [Present
was 01 July 2015]
1 QOL.tw. (22113)
2 “Value of Life”/ (5451)
3 “Quality of Life”/ (127151)
4 Quality of Life.tw. (167265)
5 life quality.tw. (4138)
6 HRQL.tw. (2579)
7 HRQoL.tw. (8786)
8 health related quality of life.tw. (25458)
9 patient$ attitude$.tw. (2041)
10 Attitude to Health/ (74599)
11 well$ being.tw. (44383)
12 “Cost of Illness”/ (19159)
13 Emotions/ (45846)
14 (burden adj3 (illness or
disease$)).tw.
(17382)
15 (burden adj3 illness).tw. (1870)
16 Adaptation, Psychological/ (77385)
17 (cope or coping).tw. (55257)
18 (patient$ adj10 (cope or
coping)).tw.
(7386)
19 (value adj2 life).tw. (589)
20 psychological adaptation.tw. (432)
21 psychological$ adapt$.tw. (499)
22 (psychological$ adj3 adapt$).tw. (856)
23 or/1e22 (475533)
24 short bowel syndrome$1.tw. (2458)
25 short gut syndrome$1.tw. (276)
26 short intestinal syndrome$1.tw. (3)
27 short intestine syndrome$1.tw. (26)
28 chronic intestinal failure.tw. (74)
29 if type 3.tw. (2)
30 if type iii.tw. (2)
31 short bowel syndrome/ (2455)
32 or/24e31 (3543)
33 23 and 32 (220)
34 limit 33 to (English language
and last 10 years)
(88)
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